US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

19.19

-1.0000-4.95%

Post-market: 18.59-0.6000-3.13%18:53 EDT

Volume:289.67K

Turnover:5.55M

Market Cap:547.19M

PE:30.95

High:19.58

Open:18.87

Low:18.75

Close:20.19

Loading ...

Overview Company News Filings

FDA Accepts Cytokinetics' Application for Cardiovascular Drug

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Grifols Stock Declines After Brookfield Drops Buyout Offer

Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Corcept Shares Rise More Than 60% in Three Months: Here's Why

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSTL/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":19.19,"timestamp":1743710400000,"preClose":20.19,"halted":0,"volume":289672,"hourTrading":{"tag":"盘后","latestPrice":18.59,"preClose":19.19,"latestTime":"18:53 EDT","volume":14127,"amount":271096.677936,"timestamp":1743720824022},"delay":0,"floatShares":27722551,"shares":28514109,"eps":0.62,"marketStatus":"Closed","change":-1,"latestTime":"04-03 16:00:00 EDT","open":18.87,"high":19.58,"low":18.75,"amount":5545251.92712,"amplitude":0.041109,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.62,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":5,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":20.19,"preHourTrading":{"tag":"盘前","latestPrice":18.59,"preClose":20.19,"latestTime":"08:58 EDT","volume":129,"amount":2403.559992,"timestamp":1743685126556},"postHourTrading":{"tag":"盘后","latestPrice":18.59,"preClose":19.19,"latestTime":"18:53 EDT","volume":14127,"amount":271096.677936,"timestamp":1743720824022},"volumeRatio":1.189174,"impliedVol":0.421,"impliedVolPercentile":0.1275},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":27722551,"roa":"1.10%","roe":"4.31%","lyrEps":0.656862,"volumeRatio":1.189174,"shares":28514109,"dividePrice":0,"high":19.58,"amplitude":0.041109,"preClose":20.19,"low":18.75,"week52Low":16.965,"pbRate":"1.20","psRate":"1.65","week52High":35.84,"institutionHeld":0,"latestPrice":19.19,"eps":0.62,"divideRate":0,"volume":289672,"delay":0,"ttmEps":0.62,"open":18.87,"prevYearClose":26.65,"prevWeekClose":19.94,"prevMonthClose":20.02,"prevQuarterClose":20.02,"fiveDayClose":20.1,"twentyDayClose":20.59,"sixtyDayClose":29.36},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2488097839","title":"FDA Accepts Cytokinetics' Application for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488097839","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488097839?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:37","pubTimestamp":1733251020,"startTime":"0","endTime":"0","summary":"Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application  for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval of the candidate for the treatment of obstructive hypertrophic cardiomyopathy .Year to date, Cytokinetics’ shares have lost 39.5% compared with the industry’s 7% decline.The NDA is supported by the results from the phase III SEQUOIA-HCM  study on aficamten in patients with symptomatic obstructive HCM.Results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo.Meanwhile, Bayer AG BAYRY will acquire rights to aficamten in Japan. As per the joint development plan, Bayer plans to conduct a phas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCM","BK4139","BK4505","CYTK","BAYRY","CSTL","BK4531","BK4196","SPRO","BK4585","BK4588","BK4007","CSII","BK4082"],"gpt_icon":0},{"id":"2488507978","title":"PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488507978","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488507978?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:36","pubTimestamp":1733250960,"startTime":"0","endTime":"0","summary":"Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518, its investigational oral therapy for Huntington's disease .Per the terms of the deal, Novartis will be responsible for developing and marketing PTC518 in HD indication after completion of the ongoing phase II PIVOT-HD study, expected in the first half of next year. PTC Therapeutics will receive an upfront cash payment of $1 billion. The company will also be eligible to receive up to $1.9 billion in milestone payments from Novartis.While both companies will share profits and losses in the United States in the ratio of 40:60 , NVS will be responsible for ex-U.S. sales. PTCT will also be eligible to receive tiered double-digit royalties on ex-U.S. sales of the drug.The deal is expected to be closed in first-quarter 2025, subject to the fulfillment of customary closing conditions, including r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","LU0354030511.USD","LU1093756168.USD","SPRO","BK4083","IE00BWXC8680.SGD","BK4196","IE00B1XK9C88.USD","IE00BJT1NW94.SGD","BK4566","SG9999001440.SGD","LU1035775433.USD","LU1551013425.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU1929549753.HKD","LU0820561818.USD","IE00BSNM7G36.USD","LU1989772923.USD","LU0354030438.USD","LU0942090050.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU0211331839.USD","CSTL","LU1496350171.SGD","IE00B4R5TH58.HKD","LU0868494708.USD","LU0234572021.USD","LU0820562030.AUD","BK4530","LU0079474960.USD","LU2756315664.SGD","LU1093756325.SGD","CRL","LU0320765646.SGD","LU0689472784.USD","BK4550","BK4139","BK4121","LU1069344957.HKD","HD","LU0823434583.USD","LU0823434740.USD","PTCT","BK4534","LU0109394709.USD","NVS","BK4533"],"gpt_icon":0},{"id":"2488792925","title":"SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2488792925","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488792925?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:56","pubTimestamp":1733241360,"startTime":"0","endTime":"0","summary":"Shares of the company skyrocketed 363% on Dec. 2 following the announcement of the news.Per management, a potential first-in-class off-the-shelf CAR-NK cell therapy, SENTI-202, has been developed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, like AML, while not affecting the healthy bone marrow cells.SNTI stock has surged 51.5% so far this year against the industry’s decline of 7.1%.More on the Initial Data from SNTI's Phase I Study. Initial data from the phase I study showed that two out of the three AML patients who were treated at the lowest dose level  achieved complete remission , confirmed by bone marrow biopsy as of the data cutoff date of Sept. 19, 2024.Additionally, both patients achieved measurable residual disease  negative following treatment with SENTI-202.Per the press release, MRD negative indicates that no detectable cancer cells are present in a bone marrow sample as checked by the most sensitive locally available method.Some","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snti-stock-skyrockets-initial-data-155600334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IMCR","BK4505","CSTL","SPRO","BK4196","BK4539","SNTI"],"gpt_icon":1},{"id":"2488923995","title":"ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923995","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923995?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:06","pubTimestamp":1733238360,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions  in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol  and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C  and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the industry’s decline of 5.2%.ESPR's Nexletol & Nexlizet Approved in Other Countries. Nexletol and Nexlizet are approved for treating elevated LDL-C and cardiovascular risk reduction in the United States and Europe. The drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets  in partnership with Daiichi Sankyo.In March 2024, the FDA approved label expansions for Nexletol tablets and Nexlizet tablets to include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevent","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.vcXZvNbnFvDkPdENtrKng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.vcXZvNbnFvDkPdENtrKng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/espr-files-drug-submissions-nexletol-150600595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMCR","ESPR","CSTL","BK4139","BK4196","BK4505","BK4007","SPRO"],"gpt_icon":0},{"id":"2488957588","title":"Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957588","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957588?lang=en_us&edition=fundamental","pubTime":"2024-12-03 02:19","pubTimestamp":1733163540,"startTime":"0","endTime":"0","summary":"Shares of Allogene Therapeutics ALLO have lost nearly 23% year to date, underperforming the industry’s 7.0% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. ALLO’s shares are trading below the 50 and 200-day moving averages.ALLO Stock Underperforms Industry, Sector & S&P 500. The decline in stock price can be attributed to the strategic changes in Allogene’s pipeline, announced at the start of this year. This delayed management’s plans to bring cema-cel, its lead pipeline drug, to the market by at least a couple of years.Let’s dig into the stock’s prospects.ALLO Explores Lead Drug’s Potential as First-Line LBCL Therapy. Allogene is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases. In this regard, it plans to start an early-stage study with a new candidate, ALLO-329, in lupus/systemic lupus erythematosus  indication by first-quarter 2025 and expects to have proof-of-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-loses-23-date-181900263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCC","SLE","BK4505","BK4139","BK4077","CSTL","ALLO","SPRO","LENZ","BK4196"],"gpt_icon":0},{"id":"2487562165","title":"Mirum Shares Surge More Than 90% in 6 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2487562165","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487562165?lang=en_us&edition=fundamental","pubTime":"2024-11-29 22:59","pubTimestamp":1732892340,"startTime":"0","endTime":"0","summary":"Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli , an orally administered ileal bile acid transporter  inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis , a rare genetic disorder that causes liver failure.Livmarli sales have been rising steadily since its approval and launch worldwide.The majority of Mirum’s revenues are now being driven by Livmarli. In the first nine months of 2024, Livmarli generated sales worth $149.2 million, up 48.7% on a year-over-year basis. The continued demand for Livmarli is driving the top line and the momentum is expected to continue in the future quarters.Mirum recently initiated the phase III EXPAND study, w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-shares-surge-more-90-145900658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","IMCR","MIRM","SPRO","BK4196","BK4139","CSTL"],"gpt_icon":0},{"id":"2487934538","title":"Grifols Stock Declines After Brookfield Drops Buyout Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2487934538","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487934538?lang=en_us&edition=fundamental","pubTime":"2024-11-28 23:02","pubTimestamp":1732806120,"startTime":"0","endTime":"0","summary":"Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a common ground over the company's value. Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for 6.45 billion . Per management, the valuation “significantly undervalues the company’s fundamental prospects and its long-term potential.”This announcement puts an end to months of negotiations between Grifols and Brookfield, which, along with key shareholders of Grifols, had expressed its intent for a potential takeover in July. These key shareholders are members of the Grifols family as well as the founders of the company. Per a Bloomberg article, the Grifols family owns about a third of the company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grifols-stock-declines-brookfield-drops-150200692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BAM","BK4139","GRFS","CSTL","SPRO","BK4196","BK4585","CTMX","BK4588"],"gpt_icon":0},{"id":"2486312660","title":"Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2486312660","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486312660?lang=en_us&edition=fundamental","pubTime":"2024-11-28 20:47","pubTimestamp":1732798020,"startTime":"0","endTime":"0","summary":"U.S. stock markets have been witnessing an impressive rally since the beginning of 2023 barring some minor hurdles. Wall Street’s bull run has got an added boost this year, to the surprise of a large section of financial pandits, who indiscriminately warned of overvaluation.Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have advanced 18.6%, 26.5%, and 29.1%, respectively. Most surprising fact is that the small-cap-centric Russell 2000 index has appreciated 20.5% this year. This index suffered a severe blow in the last two years.Here, we recommend five small-cap stocks with a favorable Zacks Rank and solid upside potential for the short term. These are Talkspace Inc. TALK, Rayonier Advanced Materials Inc. RYAM, Castle Biosciences Inc. CSTL, Private Bancorp of America Inc. PBAM and Research Solutions Inc. RSSS.Since the onset of the COVID-19 pandemic in March 2020, small businesses have suffered a lot. During the pandemic, the main concern w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.wnlICCvUhE2mQs0zn8lBQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef0a203c40a8fd2c2b5a1f4904ccbe9e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.wnlICCvUhE2mQs0zn8lBQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef0a203c40a8fd2c2b5a1f4904ccbe9e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-caps-winners-2024-5-124700447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RSSS","CSTL","RYAM","BK4134","TALK","BK4196","BK4109","BK4211","ARKG","BK4209","BK4544","BK4585","PBAM","BK4588","BH"],"gpt_icon":0},{"id":"2486803311","title":"ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2486803311","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486803311?lang=en_us&edition=fundamental","pubTime":"2024-11-28 00:29","pubTimestamp":1732724940,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that its supplemental new drug application  for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET .Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.The company was notified of the update on the ODAC meeting by the FDA. ODACs mostly review and evaluate data regarding the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and make recommendations to the Commissioner of Food and Drugs.Per EXEL, the planned ODAC meeting is not related to the currently approved indications for Cabometyx in the United States.In August 2024, the FDA granted cabozantinib orphan drug designation for the treatment of pNET and assigned a target action date of April 3, 2025.EXEL’s Effort","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/odac-discuss-exelixis-application-cabometyx-162900490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU1037948541.HKD","SG9999014567.USD","LU1066051225.USD","PFS","EXEL","SG9999001176.USD","IE00BN8TJ469.HKD","RCC","LU0203345920.USD","DTC","HCC","LU0234572021.USD","IE00BBT3K403.USD","LU1093756325.SGD","LU0238689110.USD","BK4007","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU1989771016.USD","LU2089984988.USD","LU2023250843.SGD","BK4550","LU1037948897.HKD","IE00BSNM7G36.USD","LU1934455863.HKD","MRK","LU2023250504.SGD","IE00BJJMRZ35.SGD","SPRO","IE0002141913.USD","SG9999001176.SGD","BK4139","LU0058720904.USD","LU0861579265.USD","LU1989772840.SGD","BK4195","LU0265550359.USD","CSTL","LU0965509101.SGD","LU2361044865.SGD","LU2361045086.USD","BK4006","LU1116320737.USD","LU2361044949.HKD","LU1061106388.HKD","LU0965509010.AUD","SG9999014542.SGD","LU1291159041.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2486241834","title":"AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2486241834","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486241834?lang=en_us&edition=fundamental","pubTime":"2024-11-27 03:18","pubTimestamp":1732648680,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap  in certain patients with prostate cancer.The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga  and androgen deprivation therapy in patients with PTEN-deficientde novometastatic hormone-sensitive prostate cancer .Results from the study showed that patients treated with this combination achieved a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival  when compared to those patients who only received standard of care  therapy, which is JNJ’s Zytiga plus ADT.Per AstraZeneca, the above results are the first to show that adding an ATK inhibitor to SoC can benefit mHSPC patients with tumor PTEN deficiency, an aggressive form of prostate cancer with a poor prognosis. Management claims that about 200,000 patients are diagnosed with mHSP","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-combination-therapy-meets-goal-191800859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2602419157.SGD","BK4588","LU0203347892.USD","LU1506573853.SGD","BK4007","LU1066053197.SGD","OS","IE0002270589.USD","IE00BDGV0183.EUR","SG9999001440.SGD","SG9999002224.SGD","LU0912757837.SGD","LU1221951129.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B42XCP33.USD","IE00BSNM7G36.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","CSTL","BK4097","BK4165","LU1032466523.USD","LU2347655156.SGD","JNJ","LU1066051225.USD","BK4585","LU1718418525.SGD","LU0098860793.USD","LU0320765992.SGD","ADT","IE00B2B36J28.USD","LU1935042991.SGD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","CTMX","LU1267930813.SGD","LU1244550494.USD","BK4139","LU0114720955.EUR","LU0122379950.USD","LU1074936037.SGD","LU0882574055.USD","LU1261432733.SGD","LU1023059063.AUD","AZN","LU0345770308.USD","BK4534","LU2468319806.SGD","BK4533"],"gpt_icon":1},{"id":"2486886490","title":"NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486886490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486886490?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:30","pubTimestamp":1732635000,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics, Inc. NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational in vivo genome-editing candidate, Nexiguran ziclumeran .The regulatory body granted the RMAT designation to nex-z for the treatment of hereditary transthyretin  amyloidosis with polyneuropathy .The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application .Shares of Intellia were up 3.4% yesterday following the announcement of the news. However, the stock has plunged 51.6% so far this year compared with the industry’s decline of 9%.Earlier this month, the FDA cleared Intellia’s investigational new drug  application for initiating the pivotal phase III","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ntla-fda-grants-rmat-status-153000433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","LU2089984988.USD","LU0320765992.SGD","LU1917777945.USD","REGN","BK4535","NTLA","LU0889565916.HKD","CSTL","BK4588","LU0823416689.USD","LU1974910355.USD","LU0114720955.EUR","LU0109394709.USD","LU2362541513.USD","LU1861559042.SGD","SPRO","LU1861558580.USD","LU2023250504.SGD","LU0882574055.USD","LU2106854487.HKD","LU2362541273.HKD","LU2362540622.SGD","LU2468319806.SGD","BK4196","LU0053666078.USD","BK4556","LU0289739699.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2486517140","title":"Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486517140","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486517140?lang=en_us&edition=fundamental","pubTime":"2024-11-26 02:25","pubTimestamp":1732559100,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have surged 25% in a month against the industry’s decline of 4.9%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The outperformance can be attributed to better-than-expected third-quarter results. The company also raised its annual guidance.Exelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.Net revenues were $539.5 million, which easily beat the Zacks Consensus Estimate of $491 million. The top line surged 14.3% year over year.Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq , for metastatic castration-resistant prostate cancer.Another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral. Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib, in combination with Tecentriq, compared with re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-surges-25-month-182500523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1941712348.USD","BK4533","LU1989772923.USD","SG9999002232.USD","IE0009355771.USD","LU1066051811.HKD","BK4559","LU1066051225.USD","LU2089984988.USD","BK4534","EXEL","LU0208291251.USD","RCC","LU0861579265.USD","LU0289739699.SGD","LU1983299246.USD","LU1093756168.USD","CSTL","SPRO","SG9999001440.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1116320901.HKD","LU0203345920.USD","LU2023250843.SGD","BK4550","LU1974910355.USD","LU0265550946.USD","IE00BSNM7G36.USD","IE00BLSP4239.USD","MRK","LU2106854487.HKD","BK4139","LU1989771016.USD","LU2361044949.HKD","BK4196","LU1934455194.USD","IE000M9KFDE8.USD","LU0106261372.USD","LU0122379950.USD","LU0965509283.SGD","LU1023059063.AUD","LU1116320737.USD","IE00B2B36J28.USD","BK4585","LU0965509101.SGD","LU0211331839.USD","SG9999015341.SGD","SG9999015358.SGD"],"gpt_icon":0},{"id":"2486058699","title":"HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2486058699","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486058699?lang=en_us&edition=fundamental","pubTime":"2024-11-25 23:40","pubTimestamp":1732549200,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for 11.00 per share in cash. The acquisition offer implied a fully diluted equity value of 2.0 billion.Halozyme decided to withdraw the acquisition bid following the unwillingness of Evotec’s management to discuss the potential buyout offer. EVO maintained its desire to remain an independent company.Besides withdrawing the buyout offer, HALO also reaffirmed its 2024 revenue guidance that was provided last month.Shares of Halozyme were up 7.2% on Nov. 22 following the announcement of the news. The stock has rallied 32.6% so far this year against the industry’s decline of 8.5%.Earlier this month, Halozyme submitted its non-binding proposal to acquire Evotec for 11.00 per share in cash. The offer represented a premium of 109% to EVO's undisturbed share price on Oct. 15, 2024.The acquisition would have diversified HALO’s business operation and also likely extended Halozyme’s r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/halo-withdraws-acquisition-bid-evo-154000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","BK4121","BK4139","EVO","BK4196","LU0053671581.USD","CSTL","HALO"],"gpt_icon":0},{"id":"2486032556","title":"Are Medical Stocks Lagging  AnaptysBio (ANAB) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486032556","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486032556?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:40","pubTimestamp":1732545611,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AnaptysBio, Inc.  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?Let's take a closer look at the stock's year-to-date performance to find out.AnaptysBio, Inc. is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AnaptysBio, Inc. is currently sporting a Zacks Rank of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-anaptysbio-anab-144011173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4139","CSTL","ANAB"],"gpt_icon":0},{"id":"2485129286","title":"Corcept Shares Rise More Than 60% in Three Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2485129286","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485129286?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:32","pubTimestamp":1732293120,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym , which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters and the trend is likely to continue in 2025.The company is also making good progress with its promising set of pipeline candidates.Factors Driving CORT Stock in the Given Time Frame. Corcept’s top line solely comprises product sales from Korlym. The drug has been a consistent revenue driver for the company since approval. Sales of the drug increased 42.1% year over year to $493.2 million in the first nine months of 2024, owing to the strong demand and a record number of patients receiving the medication.Owing to the strong performance, CORT increased its annual revenue guidance for Korlym concurrently with third-quarter results. The company now expects total reven","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-shares-rise-more-60-163200157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4532","BK4505","BK4139","IMCR","CSTL","SPRO","BK4196","LU1559883803.SGD","BK4007","CORT"],"gpt_icon":0},{"id":"2485144543","title":"JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485144543","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485144543?lang=en_us&edition=fundamental","pubTime":"2024-11-22 01:08","pubTimestamp":1732208880,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer . The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in the country.The commercial launch of the drug is expected before this year’s end.The FDA’s approval is based on data from the phase IIb HERIZON-BTC-01 study on zanidatamab in the above indication. The study achieved its primary endpoint — patients who were treated with the drug achieved an objective response rate of 52%, with a median duration of response of 14.9 months.In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 13 cents. Estimat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-secures-fda-approval-ziihera-170800441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BTC","LU0889565916.HKD","BK4532","CSTL","BK4007","CTMX","SPRO","BK4533","LU0109394709.USD","LU0320765992.SGD","BK4139","BK4196","JAZZ"],"gpt_icon":0},{"id":"2485341065","title":"PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485341065","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485341065?lang=en_us&edition=fundamental","pubTime":"2024-11-22 00:11","pubTimestamp":1732205460,"startTime":"0","endTime":"0","summary":"Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The ALISCA-Breast1 study is investigating alisertib in combination with endocrine therapy for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative  recurrent or metastatic breast cancer in patients who have been previously treated with CDK 4/6 inhibitors and have received at least two prior lines of endocrine therapy in the recurrent or metastatic setting.The main objective of the ALISCA-Breast1 study is to determine the optimal dose of alisertib in combination with a selected endocrine therapy. Initial data from the study is expected in 2025.Upon finding the optimal dose of alisertib, PBYI plans to meet with global regulatory agencies for the design of a pivotal phase III study on the candidate. The study will evaluate alisertib plus investigator’s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pbyi-begins-phase-ii-study-161100190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4505","IMCR","CSTL","SPRO","BK4196","PBYI"],"gpt_icon":0},{"id":"2485410617","title":"SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2485410617","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485410617?lang=en_us&edition=fundamental","pubTime":"2024-11-21 23:56","pubTimestamp":1732204560,"startTime":"0","endTime":"0","summary":"Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor , for treating cognitive impairment  associated with Huntington’s Disease  failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the Symbol Digit Modalities Test, a measure of cognitive function, at day 84. This was the primary endpoint of the study.The stock hit its 52-week low on the pipeline setback. Year to date, shares of Sage Therapeutics have plunged 77.3% compared with the industry’s decline of 8.5%.An inherited disorder, HD, causes nerve cells  in brain parts to gradually break down and die. CI is one of the most under-recognized aspects of HD. Currently, no treatment options are available to improve HD-related cognitive ef","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sages-dalzanemdor-fails-meet-goal-155600924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0820562030.AUD","LU2756315664.SGD","BK4139","LU1551013425.SGD","BK4581","MCI","HD","LU0820561909.HKD","BK4505","BK4566","IMCR","LU1093756325.SGD","BK4567","BK4533","LU1169590202.USD","LU0234572021.USD","CSTL","LU2756315318.SGD","BK4588","LU0354030511.USD","IE00B1XK9C88.USD","BK4504","LU0823411888.USD","LU0943347566.SGD","LU0079474960.USD","LU1162221912.USD","LU1551013342.USD","LU0823434740.USD","LU1169589451.USD","IE00BWXC8680.SGD","SAGE","BK4023","LU1674673428.USD","SPRO","SG9999001440.SGD","LU1035775433.USD","IE00B19Z3B42.SGD","LU0942090050.USD","LU1778281490.HKD","LU0689472784.USD","LU0823434583.USD","IE00BSNM7G36.USD","BK4196","CI","IE0002270589.USD","PD","BK4083","LU0058720904.USD","BK4550"],"gpt_icon":0},{"id":"2485149103","title":"Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485149103","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485149103?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:30","pubTimestamp":1732113000,"startTime":"0","endTime":"0","summary":"Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for 6.45 billion .Per a regulatory filing submitted to the SEC, Grifols stated that the valuation offered by Brookfield “significantly undervalues the company’s fundamental prospects and its long-term potential.”Brookfield, along with key shareholders of Grifols, had expressed its intent for a potential takeover of the company in July. These key shareholders are the members of the Grifols family as well as founders of the company.Per a Bloomberg article, the Grifols family owns about a third of the company.In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 13 cents. Estimates for 2025 loss per share have narrowed","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grifols-board-rejects-brookfields-buyout-143000792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BAM","SPRO","BK4196","GRFS","CSTL","CTMX"],"gpt_icon":0},{"id":"2484903430","title":"FATE Presents Encourgaing Data From Lupus Study, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903430","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903430?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:55","pubTimestamp":1732042500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed that the first patient suffering from active lupus nephritis  and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.FT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospital","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","SPRO","SLE","BK4505","IMCR","BK4196","BK4139","CSTL","FATE"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31},{"market":"US","date":"2024-05-02","symbol":"CSTL","fiscalQuarterEnding":"2024/03","expectedEps":-0.37,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714622400000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-04-02","current":30.913076,"percent":0.798701,"low":-703.916349,"twenty":-90.550101,"median":-11.77485,"eighty":31.238148,"high":155.734424,"avg":-44.914577,"sd":149.542208,"marketCap":564009076},"quantilePoints":[{"date":"2020-04-03","current":89.105704,"twenty":-146.563592,"median":65.161453,"eighty":76.888588,"marketCap":470210799},{"date":"2020-04-09","current":91.386289,"twenty":-145.883483,"median":65.492559,"eighty":77.899964,"marketCap":482245445},{"date":"2020-04-17","current":96.436155,"twenty":-144.677835,"median":66.317311,"eighty":79.275321,"marketCap":508893589},{"date":"2020-04-24","current":96.009656,"twenty":-144.028639,"median":68.135378,"eighty":80.182781,"marketCap":506642957},{"date":"2020-05-01","current":92.390956,"twenty":-143.704042,"median":68.845748,"eighty":81.767269,"marketCap":487547076},{"date":"2020-05-08","current":102.692841,"twenty":-142.838448,"median":69.315315,"eighty":83.406552,"marketCap":541910124},{"date":"2020-05-15","current":89.505926,"twenty":-142.421108,"median":70.049766,"eighty":84.306716,"marketCap":644890198},{"date":"2020-05-22","current":90.653132,"twenty":-141.385486,"median":70.663815,"eighty":86.10245,"marketCap":653155813},{"date":"2020-05-29","current":91.848137,"twenty":-139.963439,"median":70.856459,"eighty":88.430421,"marketCap":661765829},{"date":"2020-06-05","current":90.079529,"twenty":-139.808869,"median":71.037061,"eighty":89.171324,"marketCap":649023006},{"date":"2020-06-12","current":88.478221,"twenty":-139.422443,"median":71.891914,"eighty":89.431502,"marketCap":637485584},{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-02","current":30.913076,"twenty":-90.550101,"median":-11.77485,"eighty":31.238148,"marketCap":564009076}],"updateTime":1743724804985}}}